LSE:AZN (AstraZeneca PLC)

About AZN

AstraZeneca is a biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Respiratory, Inflammation and Autoimmunity (RIA), Cardiovascular and Metabolic Disease (CVMD) and Oncology – as well as in Infection and Neuroscience.
  • AstraZeneca PLC (LSE: AZN) Latest News

    UK financial background: share prices and stock graph overlaid on an image of the Union Jack
    Investing Articles

    Here’s why the AstraZeneca share price dipped 3.7% in the FTSE 100 today

    Despite AstraZeneca’s falling share price today, this writer believes the London-listed pharmaceutical giant could be worth a closer look.

    Read more »

    British pound data
    Investing Articles

    The top 3 mistakes to avoid if the stock market crashes

    When the stock market dips, it can make even the hardiest of investors quiver at the knees. But no matter…

    Read more »

    US Tariffs street sign
    Growth Shares

    2 UK shares that could be significantly impacted by the new tariff rumours

    Jon Smith talks about why the new US sector-specific probes could mean that some related UK shares could be under…

    Read more »

    Thoughtful man using his phone while riding on a train and looking through the window
    Investing Articles

    £10,000 invested in the FTSE 100 at the start of the year is now worth…

    The FTSE 100's often incorrectly seen as a barometer for the UK economy. Donald Trump’s tariffs have demonstrated that it’s…

    Read more »

    Long-term vs short-term investing concept on a staircase
    Investing Articles

    Down 28% in 8 months, is AstraZeneca’s share price too cheap for me to pass up right now?

    AstraZeneca’s share price has fallen a long way from its September high, but this may mean an opportunity for me…

    Read more »

    Man thinking about artificial intelligence investing algorithms
    Investing Articles

    Just opened a Stocks and Shares ISA? Here are 10 stocks to consider buying, according to AI

    With the start of a new tax year, Zaven Boyrazian uses ChatGPT to build a Stocks and Shares ISA starter…

    Read more »

    Road 2025 to 2032 new year direction concept
    Investing Articles

    I asked ChatGPT where the FTSE 100 will be in 6 months: here’s what it said…

    Let’s be realistic, ChatGPT can’t predict the future. But it did do a good job of compiling data from brokerages…

    Read more »

    Mature black woman at home texting on her cell phone while sitting on the couch
    Investing Articles

    These FTSE shares may offer some safety as Trump slaps tariffs on trading partners

    FTSE shares moved lower on 3 April, after US President Donald Trump introduced hefty tariffs on its trading partners. These…

    Read more »

    UK financial background: share prices and stock graph overlaid on an image of the Union Jack
    Investing Articles

    3 top FTSE 100 shares to consider for a new ISA

    The FTSE 100 is packed with top-notch companies that can form the building blocks of a quality Stocks and Shares…

    Read more »

    Surprised Black girl holding teddy bear toy on Christmas
    Investing Articles

    A £10,000 investment in AstraZeneca shares last Christmas is now worth…

    AstraZeneca shares have enjoyed moderate gains this year, helping to recover some of last year’s losses. But does it remain…

    Read more »

    Engineer Project Manager Talks With Scientist working on Computer
    Investing Articles

    Prediction: 12 months from now, AstraZeneca’s share price could be…

    AstraZeneca is making a $1bn investment for the long term, but what lies in store for investors over the next…

    Read more »

    Businessman using pen drawing line for increasing arrow from 2024 to 2025
    Investing Articles

    £10,000 invested in AstraZeneca shares 1 year ago is now worth…

    AstraZeneca shares have recovered from their brief slump with investors broadly buoyed by the company’s long-term business prospects.

    Read more »